Abstract
In this review, we have analyzed the role of visceral obesity in the occurrence of metabolic syndrome (MetS). MetS is a common metabolic disorder that has been related recently to the increasing prevalence of obesity. The disorder is defined in various ways, but in the near future a new definition(s) should be applicable worldwide. The pathophysiology has been largely attributed, in the past years, to insulin resistance, although several epidemiological and pathophysiological data now indicate visceral obesity as a main factor in the occurrence of all the components of MetS. In view of this, relationships among visceral obesity, free fatty acids, dyslipidemia and insulin resistance have been reported. In addition, the effects of some adipocytokines and other proinflammatory factors produced by fat accumulation on the occurrence of MetS have been also emphasized. Accordingly, the “hypoadiponectinemia hypothesis” has been proposed as the most interesting to explain the pathophysiology of MetS. The epidemiologic, pathophysiologic and clinical data reported seem to indicate that MetS might be considered a fatal consequence of visceral obesity.
Similar content being viewed by others
References
Avogaro P, Crepaldi G (1965) Essential hyperlipidemia, obesity and diabetes. Diabetologia 1:137
Reaven GM (1988) Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37:1595–1607
Bays H, Abate N, Chandalia M (2005) Adiposopathy: sick fat causes high blood sugar, high blood pressure and dyslipidemia. Future Cardiol 1:39–59
Licata G, Corrao S, Parrinello G, Scaglione R (1996) Obesity and Cardiovascular diseases. Excerpta Med 1:5–166
Vague J (1947) La differenciation sexuelle, facteur determinant des formes de l’obesite. Press Med 30:339–340
Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW (1999) Body mass index and mortality in a prospective cohort of US adults. N Engl J Med 341:1097–1105
Kaplan RC, Heckbert SR, Furberg CD, Psaty BM (2002) Predictors of subsequent coronary events, stroke and death among survivors of first hospitalized myocardial infarction. J Clin Epidemiol 55:654–664
Bergman RN, Kim SP, Hsu IR, Catalano KJ, Chiu JD, Kabir M et al (2007) Abdominal obesity: role in the patophysiology of metabolic disease and cardiovascular risk. Am J Med 120:S3–S8
Reaven GM (2005) The metabolic syndrome: requiescat in pace. Clin Chem 51:931–938
Definition and classification of diabetes mellitus and its complications. Report of a WHO document. WHO/NCD/NCS/99. pp 31–33, 1999
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285:2486–2497
Balkau B, Charles MA (1999) Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 16:442–443
Grundy SM (2005) Metabolic syndrome scientific statement by the American Heart Association and the National Heart, Lung, and Blood Institute. Arterioscl Thromb Vasc Biol 25:2243–2244
Alberti KG, Zimmet P, Shaw J (2006) Metabolic syndrome: a world-wide definition. A consensus statement of the International Diabetes Federation. Diabet Med 23:469–480
Strazzullo P, Barbaro A, Siani A, Cappuccio FP, Versiero M, Schiattarella P et al (2008) Diagnostic criteria for metabolic syndrome: a comparative analysis in an unselected sample of adult male population. Metabolism 57:355–361
Matsuzawa Y (2006) The metabolic syndrome and adipocytokines. FEBS 580:2917–2921
Galletti F, Barbato A, Versiero M, Iacone R, Russo O, Barba G et al (2007) Circulating leptin levels predict the development of metabolic syndrome in middle-aged men: an 8 year follow-up study. J Hypert 25:1671–1677
Yaney GC, Corkey BE (2003) Fatty acid metabolism and insulin secretion in pancreatic beta cells. Diabetologia 46:1297–1312
Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R (2005) Metabolic syndrome. A comprehensive perspective based on interactions between obesity, diabetes and inflammation. Circulation 111:1448–14542
Licata G, Scaglione R, Avellone G, Ganguzza A, Corrao S, Arnone S et al (1995) Haemostatic function in young subjects with central obesity: relationship with left ventricular function. Metabolism 44:1417–1421
Licata G, Di Chiara T, Licata A, Triolo G, Argano C, Parrinello G et al (2003) Relationship between circulating E-selectin, DD genotype of angiotensin converting enzyme, and cardiovascular damage in central obese subjects. Metabolism 52:999–1004
Licata G, Volpe M, Scaglione R, Rubattu S (1994) Salt regulating hormones in young normotensive obese subjects. Effects of saline load. Hypertension 23(Suppl I):20–24
Scaglione R, Dichiara MA, Indovina A, Lipari R, Ganguzza A, Parrinello G, Capuana G, Merlino G, Licata G (1992) Left ventricular diastolic and systolic function in normotensive obese subjects: influence of degree and duration of obesity. Eur Heart J 13:738–742
Licata G, Scaglione R, Paterna S, Parrinello G, Indovina A, Dichiara MA, Alaimo G, Merlino G (1992) Left ventricular function response to exercise in normotensive obese subjects: influence of degree and duration of obesity. Int J Cardiol 37:223–230
Galletti F, Strazzullo P (2007) Involvement of the renin-angiotensin system in obesity: older and newer patways. NMCD 17:699–674
Sarzani R, Salvi F, Dessì-Fulgheri P, Rappelli A (2008) Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome and hypertension: an integrated view in humans. J Hypert 26:831–843
Takahashi M, Arita Y, Yamagata K (2000) Genomic structure and mutations in adipose-specific gene, adiponectin. Int J Obes Rel Metab Disord 24:861–868
Kadowaki T, Yamauchi T (2005) Adiponectin and adiponectin receptors. Endocrine Rev 26:439–451
Ouchi N, Ohishi M, Kihara S, Funahashi T, Nakamura T, Nagaretani H et al (2003) Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 42:231–232
Shibata R, Ouchi N, Ito M, Kihara S, Shiojima I, Pimentel DR et al (2004) Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 10:1384–1389
Tarquini R, Lazzeri C, Laffi G, Genuini GF (2007) Adiponectin and the cardiovascular system: from risk to disease. Intern Emerg Med 2:165–176
Hu E, Liang P, Spiegelman BM (1996) AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271:10697–10703
Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J et al (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79–83
Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE et al (2001) Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930–1935
Halleux CM, Takahashi M, Delporte ML, Detry R, Funahashi T, Matsuzawa Y et al (2001) Secretion and regulation of apM 1 gene expression in human visceral adipose tissue. Biochem Biophys Res Commun 288:1102–1107
Maeda N, Takanashi M, Funashashi T, Kihara S, Nishizawa H, Kishida K et al (2001) PPAR gamma ligands increase expression and plasma concentration of adiponectin, an adipose-derived protein. Diabetes 50:2094–2099
Diez JJ, Iglesias P (2003) The role of novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 148:293–300
Shargorodsky M, Boaz M, Goldberg Y, Matas Z, Gavish D, Fux A, Wolfson N (2009) Adiponectin and vascular properties in obese patients: is it a novel biomarker of early atherosclerosis? Int J Obes 33:553–558
Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB (2004) Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291:1730–1737
Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N et al (2003) Association of hypoadiponectinemia with coronary artery disease in men. Arterioscl Thromb Vasc Biol 23:85–89
Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S et al (2002) Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13:134–141
Koenig W, Khuseyinova N, Baumert J, Meisinger C, Lowel H (2006) Serum concentration of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany. JACC 48:1369–1372
Frystyk J, Berne C, Berglund L, Jensevik K, Flyvbjerg A, Zetelius B (2007) Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men. J Clin Endocrinol Metab 92:571–576
Sattar N, Wannamethee G, Sarwar N, Tchernova J, Cherry L, Wallace AM et al (2006) Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 114:623–629
Lawlor DA, Dawey Smith G, Ebrahim S, Thompson C, Sattar N (2005) Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J Clin Endocrinol Metab 90:5677–5683
Yang WS, Yang YC, Chen CL, Wu IL, Lu JK, Lu FH et al (2007) Adiponectin SNP276 is associated with obesity, the metabolic syndrome, and diabetes in the elderly. Am J Clin Nutr 86:509–513
Vozarova B, Stefan N, Lindsay RS, Krakoff J, Knowler WC, Funahashi T et al (2002) Low plasma adiponectin concentration do not predict weight gain in humans. Diabetes 51:2964–2967
Duncan BB, Scmidt ML, Pankow JS, Bang H, Couper D, Ballantyne CN et al (2004) Adiponectin and the development of type 2 diabetes in the atherosclerosis risk in communities study. Diabetes 53:2473–2478
Yang WS, Jeng CY, Wu TJ, Tanaka S, Funahashi T, Matsuzawa Y et al (2002) Synthetic peroxisome proliferators-activated receptor gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 25:376–380
Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N et al (2003) Blockade of the renin-angiotensin system increases adiponectin concentration in patients with essential hypertension. Hypertension 42:76–81
Conflict of interest statement
The authors declare that they have no conflict of interest related to the publication of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Additional information
An erratum to this article can be found at http://dx.doi.org/10.1007/s11739-010-0419-0
Rights and permissions
About this article
Cite this article
Scaglione, R., Di Chiara, T., Cariello, T. et al. Visceral obesity and metabolic syndrome: two faces of the same medal?. Intern Emerg Med 5, 111–119 (2010). https://doi.org/10.1007/s11739-009-0332-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11739-009-0332-6